dc.contributor.author | Prentice, RE | |
dc.contributor.author | Tjandra, D | |
dc.contributor.author | Garg, M | |
dc.contributor.author | Lubel, JS | |
dc.contributor.author | Fourlanos, S | |
dc.contributor.author | Johnson, D | |
dc.contributor.author | Al-Ani, A | |
dc.contributor.author | Christensen, B | |
dc.date.accessioned | 2020-12-16T23:52:20Z | |
dc.date.available | 2020-12-16T23:52:20Z | |
dc.date.issued | 2020-10 | |
dc.identifier.citation | Prentice, R. E., Tjandra, D., Garg, M., Lubel, J. S., Fourlanos, S., Johnson, D., Al-Ani, A. & Christensen, B. (2020). Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.. Aliment Pharmacol Ther, 52 (8), pp.1422-1423. https://doi.org/10.1111/apt.16063. | |
dc.identifier.issn | 0269-2813 | |
dc.identifier.uri | http://hdl.handle.net/11343/254607 | |
dc.language | eng | |
dc.title | Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. | |
dc.type | Journal Article | |
dc.identifier.doi | 10.1111/apt.16063 | |
melbourne.affiliation.department | Medical Education | |
melbourne.affiliation.department | Medicine and Radiology | |
melbourne.source.title | Alimentary Pharmacology and Therapeutics | |
melbourne.source.volume | 52 | |
melbourne.source.issue | 8 | |
melbourne.source.pages | 1422-1423 | |
melbourne.elementsid | 1466451 | |
melbourne.openaccess.url | https://europepmc.org/articles/PMC7537250?pdf=render | |
melbourne.openaccess.pmc | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537250 | |
melbourne.openaccess.status | Published version | |
melbourne.contributor.author | Fourlanos, Spiros | |
melbourne.contributor.author | Johnson, Douglas | |
melbourne.contributor.author | Garg, Mayur | |
dc.identifier.eissn | 1365-2036 | |
melbourne.accessrights | Access this item via the Open Access location | |